DOACs plasma levels in relation to clinical outcome. How far have wecome?
Direct oral anticoagulants (DOACs) are the preferred treatment for prevention of ischemic stroke (IS) and systemic embolism (SE) in nonvalvular atrial fibrillation (NVAF) and treatment or prevention of venous thromboembolism (VTE) [1]. DOACs are administered in fixed doses and do not require routine laboratory monitoring [2]. Nonetheless, high interindividual variability of DOAC blood levels has been reported and the correlation between DOAC plasma levels and clinical outcome is still a grey area.
Source: Thrombosis Research - Category: Hematology Authors: Rosa Talerico, Roberto Pola, Menno Volkert Huisman, Frederikus Albertus Klok Tags: Letter to the Editors-in-Chief Source Type: research
More News: Atrial Fibrillation | Hematology | Ischemic Stroke | Laboratory Medicine | Men | Stroke | Thrombosis